CLC Number:
| [1] Saleem AF, Qamar FN, Shahzad H, et al. Trends in antibiotic susceptibility and incidence of late-onset Klebsiella pneumoniae neonatal sepsis over a six-year period in a neonatal intensive care unit in Karachi, Pakistan[J]. Int J Infect Dis, 2013, 17(11): 961-965. [2] Gupta S, Govil D, Kakar PN, et al. Colistin and polymyxin B: a re-emergence[J]. Indian J Crit Care Med, 2009, 13(2): 49-53. [3] Thomas R, Velaphi S, Ellis S, et al. The use of polymyxins to treat carbapenem resistant infections in neonates and children [J]. Expert Opin Pharmacother, 2019, 20(4): 415-422. [4] 中华医学会儿科学分会新生儿学组,中国医师协会新生儿科医师分会感染专业委员会. 新生儿败血症诊断及治疗专家共识(2019年版)[J].中华儿科杂志,2019, 57(4): 252-257. [5] 杨素艳,孙夫强,段洋.早发型败血症早产儿脐血培养价值研究[J].中国全科医学,2020,23(27): 3422-3426. YANG Suyan, SUN Fuqiang, DUAN Yang. The value of umbilical cord blood culture in premature infants with early-onset sepsis [J].Chinese General Practice, 2020, 23(27): 3422-3426. [6] Puopolo KM, Benitz WE, Zaoutis TE, et al. Management of neonates born at ≤34 6/7 weeks' gestation with suspected or proven early-onset bacterial sepsis[J]. Pediatrics, 2018, 142(6): e20182896. [7] 李正红,王丹华.新生儿早发型败血症的临床特点[J].中华围产医学杂志, 2011,14(7): 420-424. [8] Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis[J]. Lancet, 2017, 390(10104): 1770-1780. [9] 张武栋.早产儿及足月儿新生儿败血症临床特征比较[J]. 中国卫生标准管理, 2020,11(18): 36-38. [10] 袁莹,杨颖.多黏菌素B和E:如何选择[J].中国感染控制杂志,2017, 16(7): 677-682. [11] Richards M, Thursky K, Buising K. Epidemiology, prevalence, and sites of infections in intensive care units[J]. Semin Respir Crit Care Med, 2003, 24(1): 3-22. [12] Ylipalosaari P, Ala-Kokko TI, Laurila J, et al. Intensive care acquired infection is an independent risk factor for hospital mortality: a prospective cohort study[J]. Crit Care, 2006, 10(2): R66. [13] Piparsania S, Rajput N, Bhatambare G. Intraventricular polymyxin B for the treatment of neonatal meningo-ventriculitis caused by multi-resistant Acinetobacter baumannii-case report and review of literature[J]. Turk J Pediatr, 2012, 54(5): 548-554. [14] Al-Lawama M, Aljbour H, Tanash A, et al. Intravenous Colistin in the treatment of multidrug-resistant Acinetobacter in neonates[J]. Ann Clin Microbio Antimicrob, 2016, 15: 8. doi: 10.1186/s12941-016-0126-4. [15] Zakuan ZD, Suresh K. Rational use of intravenous polymyxin B and colistin: a review[J]. Med J Malaysia, 2018, 73(5): 351-359. [16] Rigatto MH, Oliveira MS, Perdigão-Neto LV, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B[J]. Antimicrob Agents Chemother, 2016, 60(4): 2443-2449. [17] Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy[J]. Antimicrob Agents Chemother, 2014, 58(5): 2740-2746. [18] Kelesidis T, Falagas ME. The safety of polymyxin antibiotics[J]. Expert Opin Drug Saf, 2015, 14(11): 1687-1701. [19] Zavascki AP, Manfro RC, Maciel RA, et al. Head and neck hyperpigmentation probably associated with polymyxin B therapy[J]. Ann Pharmacother, 2015, 49(10): 1171-1172. [20] Gothwal S, Meena K, Sharma SD. Polymyxin B induced generalized hyperpigmentation in neonates[J]. Indian J Pediatr, 2016, 83(2): 179-180. |
| [1] |
CI Chun-yan, LI Wen, LU Xian-mei .
Analysis of amplitude integrated electroencephalography characteristics in preterm infants [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 109-112. |
| [2] | WANG Yin,ZHU Wei-wei,LUO Huan-hua,JI Chao. Correlations between the blood motilin and gastrin levels in premature infants [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(7): 708-710. |
|
